Experts
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Telix Pharmaceuticals.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Lumos down 65pc on FDA rejection; and is Hexima belly-up after Phase 2 readout?
Health & Biotech
ASX Health Stocks: Telix seeks FDA approval for Illucix; Chimeric releases viral vector
News
Market highlights and 5 ASX Small Caps to watch on Tuesday
Health & Biotech
ASX Health Stocks: Mesoblast’s Q3 revenues, Osprey restructures business to reduce debt
News
ASX Large Caps: Tech index climbs 4pc amid hopes US inflation may have peaked
Health & Biotech
ASX Health Stocks: Invion demonstrates efficacy, Biotron gets feedback from the FDA
Experts
ScoPo’s Powerplays: Green shoots appear among smaller ASX health stocks
News
ASX Large Caps: Blue chips on a roll as investors shrug off recession fears
Experts
ScoPo’s Powerplays: Which ASX health stocks are winners from the Federal Budget?
News
Closing Bell: Tech stocks, consumer names lead as small caps close higher
News
ASX Large Caps: Bull run continues as ASX 200 notches six gains in a row
Health & Biotech
ASX Health Stocks: CBD gel could become cornerstone therapy for hand arthritis, says Avecho
Health & Biotech
ASX Health Stocks: Telix takes major leap forward on Phase 3 ZIRCON study of kidney cancer
Health & Biotech
ASX Health Stocks: Healthcare index surges as CSL revels in blood plasma boom
Health & Biotech
ASX Health Stocks: Resonance gets green light in US
Experts
SocPo’s Powerplays: A few healthcare gems among the carnage
News